-transparent.png){kind=logo}
Serum copper level was determined before operation in 179 patients with various histologically proved gynecologic tumors: malignant, benign, or metastases to the ovary. Serum copper level was significantly higher (p less than 0.01) in all groups of patients with cancer and in the benign group when compared with control subjects. Serum copper level correlated well with stage of cancer disease (r = 0.70 to 0.79) except for ovarian carcinoma, in which serum copper level was already significantly elevated in Stages I and II. The sensitivity of serum copper level greater than 150 micrograms/dl in detecting malignancy was 87% to 100% in late cancer stages in all malignancies. Our data imply that the addition of serum copper level determination to other screening tests could increase their sensitivity.
E J Margalioth, and
R Udassin, and
C Cohen, and
J Maor, and
S O Anteby, and
J G Schenker
January 1995,
Oncology,
E J Margalioth, and
R Udassin, and
C Cohen, and
J Maor, and
S O Anteby, and
J G Schenker
May 1993,
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society,
E J Margalioth, and
R Udassin, and
C Cohen, and
J Maor, and
S O Anteby, and
J G Schenker
January 1994,
Cancer chemotherapy and biological response modifiers,
E J Margalioth, and
R Udassin, and
C Cohen, and
J Maor, and
S O Anteby, and
J G Schenker
February 2020,
Hematology/oncology clinics of North America,
E J Margalioth, and
R Udassin, and
C Cohen, and
J Maor, and
S O Anteby, and
J G Schenker
July 1997,
Tanpakushitsu kakusan koso. Protein, nucleic acid, enzyme,
E J Margalioth, and
R Udassin, and
C Cohen, and
J Maor, and
S O Anteby, and
J G Schenker
April 2008,
The Surgical clinics of North America,
E J Margalioth, and
R Udassin, and
C Cohen, and
J Maor, and
S O Anteby, and
J G Schenker
January 1993,
Cancer chemotherapy and biological response modifiers,
E J Margalioth, and
R Udassin, and
C Cohen, and
J Maor, and
S O Anteby, and
J G Schenker
June 1996,
Nihon rinsho. Japanese journal of clinical medicine,
E J Margalioth, and
R Udassin, and
C Cohen, and
J Maor, and
S O Anteby, and
J G Schenker
January 1988,
Cancer chemotherapy and biological response modifiers,
E J Margalioth, and
R Udassin, and
C Cohen, and
J Maor, and
S O Anteby, and
J G Schenker
January 1987,
Cancer chemotherapy and biological response modifiers,
